Pharmaceutical Technology's Annual Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Annual Employment Survey
Nearly 1300 pharmaceutical employees provide insights into the issues most relevant to their jobs and the state of the industry workforce today.


Pharmaceutical Technology



Table III.Percentage of respondents receiving the following employer-provided benefits.
Benefits. The most common benefits include health insurance; dental, vision, or supplemental health insurance; life insurance; and employer-provided 401k match contributions (see Table III). Approximately 70% of employees also receive reimbursement for supplemental training or conference attendance.

On average, employees are granted 10 paid public holidays and 18 paid vacation days, though most took only 15 of these days for vacation and admitted to doing some work (e.g., checking e-mail, returning calls) for at least 4 of these days (one more day than last year).

Attitudes toward current employment

Participants indicated how strongly they agreed or disagreed with the following statements:
  • I believe my work is fully valued by my employer.
  • I believe my present job is secure.
  • In my present job, I use my skills and training to the fullest extent.
  • Given the opportunity, I would leave my present job.


Table IV: Opinions toward current employment.
Most respondents feel secure in their jobs, agree that their employer values their work, and believe that they use their skills to the fullest extent in their present jobs (see Table IV). Nonetheless, 38% either agreed or strongly agreed that they would leave their present job if given the opportunity, this is a sharp contrast to the 53% who responded the same last year. Employees seem less willing to leave their job in a less secure job market. Last year, 68% felt their job was secure, while this year, this value is only 60%.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here